IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests

IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices. President and CEO Mike Erickson said the company sees a long-term opportunity to expand diagnostic testing as pets live longer and veterinary practices adopt more preventive screening. He said IDEXX estimates that blood work and urinalysis identify clinically meaningful abnormalities in roughly one in four apparently healthy pets, while diagnostic testing also drives broader practice activity, including medical services, therapeutics and prescription diets. Erickson said only 13% of U.S. wellness visits currently include blood work, leaving substantial headroom for growth. IDEXX estimates that sector-wide blood-work inclusion has increased by about 50 basis points annually, contributing roughly 150 basis points of incremental recurring CAG diagnostic revenue for the company each year. The company emphasized its “Technology for Life” approach of adding new testing capabilities to existing installed instruments. IDEXX introduced quantitative proBNP cardiac testing for both dogs and cats on its Catalyst point-of-care platform. The company said the test will help veterinarians evaluate cardiac risk and make referral or monitoring decisions during patient visits. IDEXX also discussed continued adoption of its inVue Dx cytology platform. Erickson said the company had placed more than 9,000 inVue Dx instruments globally through the second quarter, with utilization per instrument in the previously stated range of $3,500 to $5,500. The platform supports ear cytology, blood morphology and fine-needle aspirate testing, or FNA. Puja Pathak, senior vice president and general manager of IDEXX VetLab, said inVue Dx is designed to reduce hands-on work, standardize results and automatically integrate findings into practice records and invoices. She said practices adopting inVue Dx have seen 6% higher ProCyte CBC utilization. IDEXX expects broad availability of the inVue FNA application by the end of the year following a controlled rollout. The company said FNA testing on inVue Dx can enable veterinarians to assess lumps and bumps in-practice, reducing the cost and complexity associated with traditional slide preparation and outside laboratory review. According to IDEXX, practices adopting the application are examining twice as many masses. Erickson also said IDEXX plans to provide further details on MultiCue Dx, a new point-of-care diagnostic platform, at VMX in Orlando in January. He described MultiCue as comp...